What is Visit?
Visit operates as a sophisticated AI-driven platform designed to bridge the gap between patient symptoms and clinical intervention. By providing an intuitive interface for symptom diagnosis, lifestyle management, and chronic condition oversight, the company effectively democratizes access to specialized medical consultations. Its market position is defined by a unique synthesis of B2B and B2C health-tech services, enabling users to navigate complex healthcare ecosystems with ease. The platform's ability to integrate seamlessly with existing medical infrastructure positions it as a vital tool for modern health management, particularly in regions where accessible, high-quality medical advice is in high demand.
How much funding has Visit raised?
Visit has raised a total of $31.1M across 2 funding rounds:
Angel/Seed
$1.4M
Stock Offering
$29.7M
Angel/Seed (2021): $1.4M with participation from Rohit Bansal, Murali Krishna, MapmyIndia, and Kunal Bahl
Stock Issuance/Offering (2024): $29.7M led by Docprime
Key Investors in Visit
Docprime
Docprime is a comprehensive healthcare platform that simplifies healthcare and insurance benefits by offering services such as online consultations, claims management, and wellness tracking.
MapmyIndia
MapmyIndia is India’s leading provider of advanced digital maps, geospatial software, and location-based IoT technologies, serving as a market leader in B2B and B2B2C geospatial products.
Rohit Bansal
A prominent angel investor and entrepreneur known for supporting high-growth technology ventures in the Indian startup ecosystem.
What's next for Visit?
With the successful closure of this major strategic investment, Visit is well-positioned to accelerate its product development roadmap and expand its footprint in the competitive digital health landscape. The company is expected to focus on deepening its AI diagnostic accuracy and broadening its network of specialist consultations to address a wider array of chronic conditions. Furthermore, the strategic alignment with its current investor base suggests a move toward deeper integration with existing healthcare and insurance ecosystems, potentially unlocking new revenue streams through enterprise-level partnerships. As the company matures, the focus will likely shift toward sustainable scaling and the refinement of its proprietary health-tech algorithms to maintain its competitive edge in the evolving global health market.
See full Visit company page
